23 related articles for article (PubMed ID: 28045167)
1. Drug Delivery to the Brain: Recent Advances and Unmet Challenges.
Bhunia S; Kolishetti N; Vashist A; Yndart Arias A; Brooks D; Nair M
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38139999
[TBL] [Abstract][Full Text] [Related]
2. Au-CGKRK Nanoconjugates for Combating Cancer through T-Cell-Driven Therapeutic RNA Interference.
Gulla SK; Kotcherlakota R; Nimushakavi S; Nimmu NV; Khalid S; Patra CR; Chaudhuri A
ACS Omega; 2018 Aug; 3(8):8663-8676. PubMed ID: 31458997
[TBL] [Abstract][Full Text] [Related]
3. Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles.
Liu Y; Song Z; Zheng N; Nagasaka K; Yin L; Cheng J
Nanoscale; 2018 Aug; 10(32):15339-15349. PubMed ID: 30070662
[TBL] [Abstract][Full Text] [Related]
4. Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo.
Wen Y; Zhang W; Gong N; Wang YF; Guo HB; Guo W; Wang PC; Liang XJ
Nanoscale; 2017 Oct; 9(38):14347-14356. PubMed ID: 28731112
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers.
Pastorino F; Brignole C; Di Paolo D; Perri P; Curnis F; Corti A; Ponzoni M
Small; 2019 Mar; 15(10):e1804591. PubMed ID: 30706636
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference.
Majumder P; Bhunia S; Bhattacharyya J; Chaudhuri A
J Control Release; 2014 Apr; 180():100-8. PubMed ID: 24556418
[TBL] [Abstract][Full Text] [Related]
7. Targeting cell cycle protein in gastric cancer with CDC20siRNA and anticancer drugs (doxorubicin and quercetin) co-loaded cationic PEGylated nanoniosomes.
Hemati M; Haghiralsadat F; Jafary F; Moosavizadeh S; Moradi A
Int J Nanomedicine; 2019; 14():6575-6585. PubMed ID: 31616144
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes.
Guan J; Sun J; Sun F; Lou B; Zhang D; Mashayekhi V; Sadeghi N; Storm G; Mastrobattista E; He Z
Nanoscale; 2017 Jul; 9(26):9190-9201. PubMed ID: 28650490
[TBL] [Abstract][Full Text] [Related]
9. DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.
Chang Q; Geng R; Wang S; Qu D; Kong X
Drug Deliv; 2016 Nov; 23(9):3629-3638. PubMed ID: 27749106
[TBL] [Abstract][Full Text] [Related]
10. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
11. CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma.
Bhunia S; Radha V; Chaudhuri A
Nanoscale; 2017 Jan; 9(3):1201-1212. PubMed ID: 28045167
[TBL] [Abstract][Full Text] [Related]
12. Ligand-targeted liposomal therapies of neuroblastoma.
Pastorino F; Marimpietri D; Brignole C; Di Paolo D; Pagnan G; Daga A; Piccardi F; Cilli M; Allen TM; Ponzoni M
Curr Med Chem; 2007; 14(29):3070-8. PubMed ID: 18220743
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
